Gastrointestinal Neoplasms
Conditions
Keywords
GSK5764227, Risvutatug Rezetecan, Ris-Rez, Solid Tumors, Colorectal Cancer, Pancreatic ductal adenocarcinoma
Brief summary
This study will check how well a new medicine, Risvutatug rezetecan, (Ris-Rez, also known as GSK5764227) works, how safe it is and how the body handles it in participants all around the world with advanced inoperable or metastatic gastrointestinal cancer who have previously received treatment.
Interventions
BIOLOGICALRisvutatug Rezetecan
Risvutatug Rezetecan will be administered
DRUGDrug 1
Drug 1 will be administered
DRUGDrug 2
Drug 2 will be administered
DRUGDrug 3
Drug 3 will be administered
DRUGDrug 4
Drug 4 will be administered
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place years of age at the time of signing the informed consent form (ICF). CRC Cohort * Has histologically confirmed unresectable, locally advanced or unresectable metastatic adenocarcinoma of the colon or rectum (histology defined by World Health Organization (WHO) classification). PDAC Cohort * Has histologically or cytologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of the pancreas (histology defined by WHO classification). All Cohorts * Is willing to use adequate contraception. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has an ECOG performance status of 0 or 1. * Has adequate organ function.
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: * Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease. * Has had any major surgery within 28 days prior to randomization or first dose of study intervention, depending on sub-cohort/cohort assignment * Has any history of prior allogenic or autologous bone marrow transplant or other solid organ transplant. * Has severe, uncontrolled or active cardiovascular disorders. * Has serious or poorly controlled hypertension. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Has untreated brain or Central nervous system (CNS) metastases or brain/CNS metastases that have progressed. * Has evidence of current ILD/non-infectious pneumonitis or a prior history of ILD/non-infectious pneumonitis requiring high-dose glucocorticoids Or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging. * Has ongoing adverse reaction(s) from prior therapy that has(have) not recovered to Grade 1 or to the baseline status preceding prior therapy. * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload. * Is pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Objective Response Rate (ORR) | Up to approximately 22 months | Confirmed ORR is defined as the proportion of participants who have achieved best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by investigator, according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Unconfirmed ORR | Up to approximately 37 months | Unconfirmed ORR is defined as the proportion of participants who have achieved a BOR of CR or PR as assessed by investigator, according to RECIST 1.1. |
| Duration of Response (DoR) | Up to approximately 37 months | DoR is defined as the time from the date of the first documented objective response (CR/PR as assessed by investigator according to RECIST 1.1) until the date of the first documented progressive disease (PD) or death, whichever is earlier. |
| Progression Free Survival (PFS) | Up to approximately 37 months | PFS (assessed by investigator), defined as the time from date of randomization (for participants in CRC-A and CRC-B) or the date of first dose study intervention for participants in PDAC until the earliest date of documented disease progression per RECIST 1.1 or death due to any cause. |
| Number of participants with AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs) by severity | Up to approximately 37 months | — |
| Number of participants with AEs leading to dose modifications, discontinuation of study interventions or death | Up to approximately 37 months | — |
| Changes from baseline in vital signs: Temperature (degree Celsius) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline vital signs: Respiratory rate (breaths per minute) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline vital signs: Pulse rate (beats per minute) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline vital signs: Blood pressure [millimetres of mercury (mmHg) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline in hematology parameters: [White blood cell count (WBCs per microliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline in hematology parameters: [Haemoglobin (Hgb) (grams per deciliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline in hematology parameters:[Haematocrit (Proportion of red blood cells in blood) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from Baseline haematology parameter: [Red Blood Cell Count (RBC) (million cells per microliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline haematology parameters: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils (giga cells per liter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from Baseline haematology parameter: Platelet count (cells per microliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Clinical chemistry parameters: Total Protein, Albumin (Grams per deciliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Clinical Chemistry parameters: AST/SGOT, ALT/ SGPT, ALP and CPK (International Units per liter) | Baseline (Day 1) and up to approximately 37 months | Clinical chemistry parameters such as Aspartate Aminotransferase (AST) / Serum Glutamic-Oxaloacetic Transaminase (SGOT), Alanine Aminotransferase (ALT)/ Serum Glutamic-Pyruvic Transaminase and (SGPT), Alkaline phosphatase (ALP) and Creatinine Phosphokinase (CPK) will be analysed |
| Changes from baseline Clinical Chemistry parameters: Total Bilirubin and Direct Bilirubin, Glucose, Calcium, Potassium, Sodium, Magnesium, Urea Nitrogen or urea, and Creatinine (milligrams per deciliter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Clinical Chemistry parameters: Lactate dehydrogenase, Amylase and Lipase (units per liter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Clinical Chemistry parameters: Chloride (millimoles per liter) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Clinical Chemistry parameters: Creatinine clearance (milliliters per minute) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline cardiac function: Electrocardiogram (ECG) (milliseconds) | Baseline (Day 1) and up to approximately 37 months | — |
| Changes from baseline Eastern Cooperative Oncology Group performance status (ECOG-PS) | Baseline (Day 1) and up to approximately 37 months | — |
| Maximum observed concentration (Cmax) of Risvutatug Rezetecan (conjugated antibody), GSK5757810 (small molecule toxin) and Drug 4 | Up to approximately 37 months | — |
| Time to reach Cmax (Tmax) of Risvutatug Rezetecan (conjugated antibody), GSK5757810 (small molecule toxin) and Drug 4 | Up to approximately 37 months | — |
| Area under the concentration-time curve (AUC) of Risvutatug Rezetecan (conjugated antibody),GSK5757810 (small molecule toxin) and Drug 4 | Up to approximately 37 months | — |
| Number of participants with Antidrug antibody (ADA) or Neutralizing Antibody (NAb) | Up to approximately 37 months | — |
| Titers of ADA against GSK5764227 | Up to approximately 37 months | — |
| Number of participants with symptomatic AEs, by severity, as measured by Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Up to approximately 37 months | The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes a library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE |
| Level of bother of AEs as measured by Functional Assessment of Cancer Therapy - Item GP5 (FACT-GP5) | Up to approximately 37 months | The FACT-GP5 item is a single item from the FACT-G that assesses how bothersome the side effects of treatment are for cancer patients. The item has a 5-category response scale ranging from 0 to 4. Higher scores indicate a higher degree of AE bother. |
Countries
Australia, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Japan, Mexico, Netherlands, Norway, Panama, Poland, South Korea, Spain, Sweden, United Kingdom, United States
Contacts
CONTACTUS GSK Clinical Trials Call Center
CONTACTEU GSK Clinical Trials Call Center
Outcome results
None listed